<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577001</url>
  </required_header>
  <id_info>
    <org_study_id>19-005779</org_study_id>
    <nct_id>NCT04577001</nct_id>
  </id_info>
  <brief_title>Letrozole in Patients With Hepatopulmonary Syndrome</brief_title>
  <official_title>Letrozole in Patients With Hepatopulmonary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and possible benefit of&#xD;
      letrozole compared to placebo in patients with Hepatopulmonary Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase II randomized, double-blind, placebo-controlled parallel trial of 20&#xD;
      subjects with hepatopulmonary syndrome designed to assess the effect of letrozole 2.5 mg&#xD;
      orally daily or placebo for 6 months on the alveolar-arterial oxygen gradient (AaPO2).&#xD;
&#xD;
      Subjects at each site will be screened at outpatient clinic visit appointments and interested&#xD;
      qualified subjects will be consented and offered participation in this trial. Once consent&#xD;
      has been obtained baseline values will be established and subjects will begin letrozole with&#xD;
      follow-up clinic visits and testing at 3 months, and 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alveolar-Arterial Oxygen</measure>
    <time_frame>6 months</time_frame>
    <description>To determine whether letrozole affects alveolar-arterial oxygen gradient (AaPO2) at 6 months in patients with HPS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hormone Levels</measure>
    <time_frame>6 months</time_frame>
    <description>To determine whether letrozole affects estradiol, progesterone, testosterone levels at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Saturation</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>• To determine whether letrozole affects oxygen saturation from pulse oximetry at 3 months 6 months and distance walked in 6 minutes in patients with HPS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>6 months</time_frame>
    <description>• To determine the safety and adverse effects associated with letrozole administration in patients with HPS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatopulmonary Syndrome</condition>
  <arm_group>
    <arm_group_label>Letrozole Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with hepatopulmonary syndrome will get the study drug letrozole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with hepatopulmonary syndrome will get the study placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>2.5 mg orally daily for 6 months</description>
    <arm_group_label>Letrozole Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>No active ingredient taken orally daily for 6 months</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Diagnosis of moderate to very severe hepatopulmonary syndrome which consists of having&#xD;
             all 3 of the following conditions:&#xD;
&#xD;
               -  Presence of liver disease or portal hypertension&#xD;
&#xD;
               -  Intrapulmonary shunting on contrast-enhanced echocardiogram&#xD;
&#xD;
               -  Hypoxemia [A-a gradient ≥15mmHg (or ≥20mmHg if age &gt;64) and PaO2&lt;80mmHg on&#xD;
                  arterial blood gas testing]&#xD;
&#xD;
          -  Child-Pugh class A or B liver disease&#xD;
&#xD;
          -  MELD score &lt; 20&#xD;
&#xD;
          -  ≥ 18 years old&#xD;
&#xD;
          -  Female subjects must be post-menopausal (defined as 12 months of spontaneous&#xD;
             amenorrhea or 6 weeks postsurgical bilateral oophorectomy without or without&#xD;
             hysterectomy)&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Enrollment in a clinical trial or concurrent use of another investigational drug or&#xD;
             device therapy (i.e., outside of study treatment) during, or within 28 days of&#xD;
             baseline&#xD;
&#xD;
          -  Current hepatic encephalopathy&#xD;
&#xD;
          -  Expectation of liver transplant within six months of randomization&#xD;
&#xD;
          -  MELD exception score &gt; 28&#xD;
&#xD;
          -  Concomitant lung disease defined as restriction (TLC &lt; 70%) or obstruction (FEV1 &lt; 80%&#xD;
             &amp; FEV1/FVC &lt; 70%)&#xD;
&#xD;
          -  Inability to comply with the study protocol&#xD;
&#xD;
          -  Osteoporosis&#xD;
&#xD;
          -  Premenopausal women (those who have not reached 1 year absence of menarche)&#xD;
&#xD;
          -  Vulnerable study population, including imprisoned individuals, non-English speaking&#xD;
             patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hilary M DuBrock, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jackie Reiter</last_name>
    <phone>(507) 538-2224</phone>
    <email>Reiter.Jacqulyn@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Kelly, M.D</last_name>
      <email>Yvonne.Kelly@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Yvonne Kelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie R Reiter</last_name>
      <phone>507-538-2224</phone>
      <email>Reiter.Jacqulyn@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2020</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Hilary M. DuBrock,</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatopulmonary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

